GSK at ERS
INTERNATIONAL CONGRESS 2019
MADRID Spain, 28 Sept - 2 Oct
Visit GSK (G.02 and H.01) to find out about our innovative science. Be sure to attend our three symposia and don't miss our daily lunchtime forum discussions with subject matter experts. This year we mark 50 years of respiratory innovation. We welcome you to help us begin our next 50 years of innovation, living every breath.
Not going to ERS? Stay tuned for videos and summaries post-event!
SCHEDULE OF EVENTS
Sun 29 Sept
Evening Symposium Can a reduction in risk lead to an improvement in asthma control?
17:15 − 19:15
Respiratory Forum at GSK stand
12:45 − 14:45
Sun 29 Sept
Evening Symposium Can a reduction in risk lead to an improvement in asthma control?
17:15 − 19:15 N104
Key Speakers
Time
Can a reduction in risk lead to an improvement in asthma control?
Speakers
17:15 − 17:25
Chairman’s introduction
Dr. Luis Perez de Llano
Dr. David Leather
17:25 − 17:45
Why at all stages of disease do we need to strive to gain asthma control
Prof. Andrew Greening
17:45 − 18:05
Learning from the past to advance and optimise care:
Don’t forget the things we have already learned
Prof. Tari Haahtela
18:05 − 18:25
Evidence of effectiveness in asthma
Prof. Ashley Woodcock
18:25 − 18:55
Why striving for effectiveness in maintenance therapy could lead to a reduction in risk
Prof. Huib Kerstjens
18:55 − 19:15
Q&A
Dr. Luis Perez de Llano
Dr. David Leather
17:15 − 17:25
Dr. Luis Perez de Llano
Dr David Leather
Chairman’s introduction
17:25 − 17:45
Prof. Andrew Greening
Why at all stages of disease do we need to strive to gain asthma control
17:45 − 18:05
Prof. Tari Haahtela
Learning from the past to advance and optimise care: Don’t forget the things we have already learned
18:05 − 18:25
Prof. Ashley Woodcock
Evidence of effectiveness in asthma
18:25 − 18:55
Prof. Huib Kerstjens
Why striving for effectiveness in maintenance therapy could lead to a reduction in risk
18:55 − 19:15
Dr. Luis Perez de Llano
Dr David Leather
Q&A
Description
We will discuss the importance of designing drugs for effectiveness — including the use of potent molecules that provide proven efficacy and reduced safety issues — as well as the factors that can drive increased asthma control.
RESPIRATORY FORUMS
Discuss the latest key areas of interest with GSK global medical experts, live on our Commercial stand.
Discussion Themes
Time
Speakers
A treatable traits approach to management of the symptomatic breathless patient: learnings from the recent EMAX trial
12:45 − 13:15
TBC
Nucala (Mepolizumab) : The long-term efficacy evidence supporting clinician’s choice
13:30 − 14:00
TBC
A treatable traits approach to managing the patient at risk of exacerbations: the latest data from the IMPACT trial
14:15 − 14:45
TBC
12:45 − 13:15
TBC
A treatable traits approach to management of the symptomatic breathless patient: learnings from the recent EMAX trial
13:30 − 14:00
TBC
Nucala (Mepolizumab) : The long-term efficacy evidence supporting clinician’s choice
14:15 − 14:45
TBC
A treatable traits approach to managing the patient at risk of exacerbations: the latest data from the IMPACT trial
Mon 30 Sept
Evening Symposium Are we doing too little too late in COPD management?
17:15 − 19:15
Respiratory Forum at GSK stand
12:45 − 14:45
Mon 30 Sept
Evening Symposium Are we doing too little too late in COPD management?
17:15 − 19:15 Room 6F
Key Speakers
Time
Are we doing too little too late in COPD management?
Speakers
17:15 − 17:25
Co-Chair’s introduction
Prof. Alvar Agusti
Co-Chair
17:25 − 17:40
Are others doing better: Can we learn from cardiologists?
Prof. David Newby
17:40 − 18:00
Can we more effectively manage COPD symptoms?
Prof. François Maltais
18:00 − 18:10
Q&A
Led by Prof. Paul Jones
and Prof. Alvar Agusti
18:10 − 18:35
Can we better manage the risk of future COPD exacerbations?
Prof. Mark Dransfield
18:35 − 18:55
Why early optimisation of the treatment of COPD matters
Prof. Neil Barnes
18:55 − 19:00
Drawing it all together: Call to Action
Prof. Paul Jones
19:00 − 19:15
Q&A
Led by Prof. Paul Jones
and Prof. Alvar Agusti
17:15 − 17:25
Prof. Alvar Agusti
Co-Chair
Co-Chair’s introduction
17:25 − 17:40
Prof. David Newby
Are others doing better: Can we learn from cardiologists?
17:40 − 18:00
Prof. François Maltais
Can we more effectively manage COPD symptoms?
18:00 − 18:10
Led by Prof. Paul Jones and
Prof. Alvar Agusti
Q&A
18:10 − 18:35
Prof. Mark Dransfield
Can we better manage the risk of future COPD exacerbations?
18:35 − 18:55
Prof. Neil Barnes
Why early optimisation of the treatment of COPD matters
18:55 − 19:00
Prof. Paul Jones
Drawing it all together: Call to Action
19:00 − 19:15
Led by Prof. Paul Jones and
Prof. Alvar Agusti
Q&A
Description
We will consider risk management strategies to manage COPD in patients with cardiovascular disease. We will discuss how to maximise symptom management and prevent future risk of exacerbations. We will also discuss the importance of starting maintenance treatment early.
RESPIRATORY FORUMS
Discuss the latest key areas of interest with GSK global medical experts, live on our Commercial stand.
Discussion Themes
Time
Speakers
A treatable traits approach to management of the symptomatic breathless patient: learnings from the recent EMAX trial
12:45 − 13:15
TBC
A treatable traits approach to managing the patient at risk of exacerbations: the latest data from the IMPACT trial
13:30 − 14:00
TBC
Nucala : ‘Power to Choose’: What does it mean for SEA patients?
14:15 − 14:45
TBC
12:45 − 13:15
TBC
A treatable traits approach to management of the symptomatic breathless patient: learnings from the recent EMAX trial
13:30 − 14:00
TBC
A treatable traits approach to managing the patient at risk of exacerbations: the latest data from the IMPACT trial
14:15 − 14:45
TBC
Nucala : ‘Power to Choose’: What does it mean for SEA patients?
Tues 1 Oct
Evening Symposium Mepolizumab completing the story: Eosinophils, real-world evidence and the power to choose
17:15 − 19:15
Respiratory Forum at GSK stand
12:45 − 14:45
Tues 1 Oct
Evening Symposium Mepolizumab completing the story: Eosinophils, real-world evidence and the power to choose
17:15 − 19:15 N104
Key Speakers
Time
Session Title
Speakers
17:15 − 17:25
Chair’s introduction
Dr. Santiago Quirce
17:25 − 17:45
Real-world evidence: A clinician’s perspective
Dr. Stephanie Korn
17:45 − 18:05
Discussion: Eosinophils in health and disease
Moderator: Prof. Neil Barnes
Dr. Peter Howarth (GSK)
and Prof. Ian Pavord (UK)
18:05 − 18:25
At-home administration: A positive choice for patients
TBC
18:25 − 18:55
Mepolizumab: A new reality for clinicians
Prof. William Busse
18:55 − 19:15
Q&A
Led by Dr. Santiago Quirce
and Prof. Neil Barnes
17:15 − 17:25
Dr. Santiago Quirce
Chair’s introduction
17:25 − 17:45
Dr. Stephanie Korn
Real-world evidence: A clinician’s perspective
17:45 − 18:05
Moderator: Prof. Neil Barnes
Dr. Peter Howarth (GSK)
and Prof. Ian Pavord (UK)

Discussion: Eosinophils in health and disease
18:05 − 18:25
TBC
At-home administration: A positive choice for patients
18:25 − 18:55
Prof. William Busse
Mepolizumab: A new reality for clinicians
18:55 − 19:15
Led by Dr. Santiago Quirce
and Prof. Neil Barnes
Q&A
Description
We will present an overview of the long-term evidence supporting the clinical efficacy and safety profile of mepolizumab in patients with severe eosinophilic asthma. We will also examine the profile of patients most likely to benefit from treatment, given the complexity introduced by an increasing number of biologic treatment options for severe asthma sub-types.
Respiratory Forums
Discuss the latest key areas of interest with GSK global medical experts, live on our Commercial stand.
Discussion Themes
Time
Speakers
Nucala : The long-term efficacy evidence supporting clinician’s choice
12:45 − 13:15
TBC
Fluticasone furoate: a modern inhaled steroid
13:30 − 14:00
TBC
Nucala : ‘Power to Choose’: What does it mean for SEA patients?
14:15 − 14:45
TBC
12:45 − 13:15
TBC
Nucala : The long-term efficacy evidence supporting clinician’s choice
13:30 − 14:00
TBC
Fluticasone furoate: a modern inhaled steroid
14:15 − 14:45
TBC
Nucala : ‘Power to Choose’: What does it mean for SEA patients?
DAILY HIGHLIGHTS
DAILY HIGHLIGHTS Each day, we will be recording the day's events and posting them on our website. Check back to review what has happened at ERS.

Adverse events should be reported. For reporting of adverse events, please write to sg.drugsafety@gsk.com


If you have any questions or comments, please contact us.
About your privacy: your privacy is important to us. To find out more, please read our privacy policy.
You can also view our website terms of use.


Anoro Ellipta, Incruse Ellipta and Relvar Ellipta were developed with Inc.


©2019 GSK Group of Companies. All rights reserved.
Trademarks are owned by or licensed to the GSK group of companies.
GlaxoSmithKline Pte Ltd, 23 Rochester Park, Singapore 139234, registered in Singapore No. 198102938K


PM-SG-RS-WCNT-190004
Date of preparation: September 2019